Details for Patent: 9,545,405

Which drugs does patent 9,545,405 protect, and when does it expire?

Patent 9,545,405 protects CIBINQO and is included in one NDA.

This patent has sixty-five patent family members in forty-four countries.

Summary for Patent: 9,545,405

Title:	Pyrrolo[2,3-D]pyrimidine derivatives
Abstract:	Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, and pharmaceutical compositions containing them.
Inventor(s):	Matthew Frank Brown, Ashley Edward Fenwick, Mark Edward Flanagan, Andrea Gonzales, Timothy Allan Johnson, Neelu Kaila, Mark J. Mitton-Fry, Joseph Walter Strohbach, Ruth E. TenBrink, John David Trzupek, Rayomand Jal Unwalla, Michael L. Vazquez, Mihir D. Parikh
Assignee:	Pfizer Corp SRL
Application Number:	US14/691,606
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,545,405
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 9,545,405

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Pfizer	CIBINQO	abrocitinib	TABLET;ORAL	213871-001	Jan 14, 2022		RX	Yes	No			Y	Y
Pfizer	CIBINQO	abrocitinib	TABLET;ORAL	213871-002	Jan 14, 2022		RX	Yes	No			Y	Y
Pfizer	CIBINQO	abrocitinib	TABLET;ORAL	213871-003	Jan 14, 2022		RX	Yes	Yes			Y	Y

International Family Members for US Patent 9,545,405

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2958921		301155	Netherlands
European Patent Office	2958921		PA2022502	Lithuania
European Patent Office	2958921		CA 2022 00003	Denmark
European Patent Office	2958921		122022000007	Germany
European Patent Office	2958921		2022C/505	Belgium
European Patent Office	2958921		LUC00261	Luxembourg
Argentina	094857